PGE2 Levels in Patient Treated With NSAIDs
Launched by UNIVERSITY OF TRIESTE · Jul 21, 2018
Trial Information
Current as of June 16, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • epiretinal membrane or full thickness macular hole scheduled for vitrectomy
- Exclusion Criteria:
- • vitreous hemorrhage
- • diabetes
- • glaucoma
- • concurrent retinovascular disease
- • previous ocular inflammation
- • previous ocular surgery
- • history of ocular trauma
- • previuos intravitreal injections
- • concomitant intake of topical or systemic NSAIDs or corticosteroid therapy
About University Of Trieste
The University of Trieste, a distinguished institution located in Italy, is committed to advancing medical research and improving healthcare outcomes through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university harnesses its expertise in various fields, including biomedical sciences, pharmacology, and clinical medicine, to conduct cutting-edge research. The institution is dedicated to adhering to the highest ethical standards and regulatory guidelines, ensuring the safety and well-being of trial participants while contributing valuable insights to the medical community. Through its robust clinical trial programs, the University of Trieste aims to translate scientific discoveries into practical applications that enhance patient care and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Trieste, Ts, Italy
Patients applied
Trial Officials
Marco R Pastore, MD
Principal Investigator
Eye Clinic, Departement of Medical Surgical Sciences and Health, University of Trieste Trieste, TS, 34129, Italy
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials